Zynerba Pharmaceuticals (ZYNE) Rating Increased to Buy at ValuEngine

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Friday, ValuEngine reports.

A number of other research firms also recently issued reports on ZYNE. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $26.00 target price on shares of Zynerba Pharmaceuticals in a research report on Monday, May 6th. Roth Capital assumed coverage on shares of Zynerba Pharmaceuticals in a research report on Tuesday, April 30th. They set a “buy” rating and a $36.00 target price on the stock. Canaccord Genuity assumed coverage on shares of Zynerba Pharmaceuticals in a research report on Monday, April 22nd. They set a “buy” rating and a $8.09 target price on the stock. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and

... read more at: https://rocklandregister.com/2019/05/17/zynerba-pharmaceuticals-zyne-rating-increased-to-buy-at-valuengine.html